The US Food and Drug Administration published a final guidance document 8 September to aid industry in preparing premarket applications (PMAs), humanitarian device exceptions (HDEs), investigational device applications (IDEs), premarket notifications (510(k)s), and de novo requests.
The guidance seeks to help sponsors submitting these applications to determine the potential for an adverse biological response that may occur when various
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?